Vilprafen Solyutab

General characteristics. Structure:

Active agent: Dzhozamitsina (in the form of a dzhozamitsin of propionate) – 1000 mg
Excipients: Microcrystallic cellulose, hydroxypropyl cellulose, sodium docusate, aspartame, silicon dioxide anhydrous, strawberry fragrance, magnesium stearate.
Description: Tablets, white or white with a yellowish shade of oblong shape, sweet, with a strawberry smell. With a text of "IOSA" and a tablet, risky on one party, and a text "1000" – on another.

Pharmacological properties:

Pharmacodynamics. Drug is used for treatment of bacterial infections; bacteriostatic activity of a dzhozamitsin, as well as other macroleads, is caused by inhibition of synthesis of protein of bacteria. During creation in the center of an inflammation of high concentration has bactericidal effect.
Dzhozamitsin is highly active concerning intracellular microorganisms (Chlamydia trachomatis and Chlamydia pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis, Ureaplasma urealyticum, Legionella pneumophila); gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae (pneumococcus), Corynebacterium diphteriae), gram-negative bacteria (Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Bordetella pertussis), and also
against some anaerobic bacteria (Peptococcus, Peptostreptococcus, Clostridium perfringens). Slightly influences enterobakteriya therefore changes a natural bacterial flora of digestive tract a little. It is effective at resistance to erythromycin. Resistance to a dzhozamitsin develops less than to other antibiotics from group of macroleads.

Pharmacokinetics. After intake джозамицин it is quickly and completely soaked up from digestive tract, meal does not influence bioavailability. The maximum concentration of a dzhozamitsin in serum is reached in 1-2 h after reception. About 15% of a dzhozamitsin contact proteins of plasma. Especially high concentration of substance are found in lungs, almonds, saliva, sweat and the lacrimal liquid. Concentration in a phlegm exceeds concentration in plasma by 8-9 times. Collects in a bone tissue. There passes the placental barrier, cosecretes in breast milk. Dzhozamitsin is metabolized in a liver to less active metabolites and excreted mainly with bile. Drug excretion with urine less than 20%.

Indications to use:

The acute and persistent infections caused by microorganisms, sensitive to drug, for example:
Upper respiratory tract infection and ENT organs:
Quinsy, pharyngitis, peritonsillitis, laryngitis, average otitis, sinusitis, diphtheria (in addition to treatment by a diphtherial anatoxin), and also scarlet fever in case of hypersensitivity to penicillin.
Lower respiratory tract infections:
Acute bronchitis, exacerbation of chronic bronchitis, pneumonia (including caused by atypical activators), whooping cough, a psittacosis.
Dental infections. Ulitis and diseases of a parodont.
Infections in ophthalmology. Blepharitis, dacryocystitis.
Infections of integuments and soft tissues. A pyoderma, a furunculosis, a malignant anthrax, an ugly face (at hypersensitivity to penicillin), eels, a lymphangitis, lymphadenitis, a venereal lymphogranuloma.

Infections of urinogenital system. Prostatitis, an urethritis, gonorrhea, syphilis (at hypersensitivity to penicillin), Chlamidia, mycoplasmal (including ureaplazmenny) and multi-infections.

Route of administration and doses:

The recommended daily dosage for adults and teenagers is aged more senior than 14 years makes from 1 to 2 g of a dzhozamitsin. In case of need the dose can be increased to 3 g a day. The daily dose has to be divided into 2-3 receptions.
The daily dosage for children is appointed calculated on the basis of 40 – 50 mg/kg of body weight daily, divided into 2-3 receptions.
 In case of ordinary and spherical eels it is recommended to appoint джозамицин in a dose 500 mg twice a day within the first 2-4 weeks, further - 500 mg of a dzhozamitsin as the supporting treatment within 8 weeks once a day.
The dispersed pill Vilprafen Solyutab can be taken in two various ways: they can be swallowed entirely, washing down with water or previously, before reception, to dissolve in water. Tablets should be dissolved at least in 20 ml of water. Before reception it is necessary to mix carefully formed suspension.
Usually duration of treatment is defined by the doctor. According to recommendations of World Health Organization about use of antibiotics duration of treatment of streptococcal infections has to make not less than 10 days.

Features of use:

At patients with a renal failure treatment should be carried out taking into account results of the corresponding laboratory tests.
It is necessary to consider a possibility of cross resistance to various antibiotics to macroleads (for example, the microorganisms steady against treatment by antibiotics, related on chemical structure, can also be rezistentna to a dzhozamitsin).

Side effects:

From digestive tract
Seldom - appetite loss, nausea, heartburn, vomiting, dysbacteriosis and diarrhea. In case of persistent heavy diarrhea it must be kept in mind a possibility of development against the background of antibiotics of life-threatening pseudomembranous colitis.
Hypersensitivity reactions:
In extremely exceptional cases skin allergic reactions are possible (for example, a small tortoiseshell).
From a liver and biliary tract
The tranzitorny increase in activity of liver enzymes in a blood plasma in rare instances accompanied with disturbance of outflow of bile and jaundice was in some cases observed.
From the hearing aid
It was in rare instances reported about a dozozavisimy passing hearing disorder.
Others: very seldom - candidiasis.

Interaction with other medicines:

Vilprafen Solyutab / other antibiotics
As bacteriostatic antibiotics can reduce bactericidal effect of other antibiotics, such as penicillin and cephalosporins, it is necessary to avoid joint purpose of a dzhozamitsin with these types of antibiotics. Dzhozamitsin it is not necessary to appoint together with lincomycin as perhaps mutual decrease in their efficiency.
Vilprafen Solyutab/ksantina
 Some   representatives   of antibiotics   of macroleads   slow down   elimination
xanthines (theophylline) that can lead to possible intoxication. Kliniko-pilot studies indicate what джозамицин exerts smaller impact on release of theophylline, than other antibiotics macroleads.
Vilprafen Solyutab / antihistaminic drugs
After the joint purpose of a dzhozamitsin and antihistaminic drugs containing терфенадин or астемизол delay of removal of a terfenadin and astemizol can be noted that in turn can lead to development of life-threatening cardiac arrhythmias.
Vilprafen Solyutab/alkaloida of an ergot
There are individual messages on strengthening of vasoconstriction after joint purpose of alkaloids of an ergot and antibiotics of macroleads. One case of absence at the patient of tolerance to ergotamine at reception of a dzhozamitsin is noted. Therefore the accompanying use of a dzhozamitsin and ergotamine has to be followed by the corresponding observation of patients.
Vilprafen Solyutab/tsiklosporin
Joint purpose of a dzhozamitsin and cyclosporine can cause increase in level of cyclosporine in a blood plasma and creation of nephrotoxic concentration of cyclosporine in blood. It is regularly necessary to control concentration of cyclosporine in plasma.
Vilprafen Solyutab/digoksin
At joint purpose of a dzhozamitsin and digoxin increase in level of the last in a blood plasma is possible.
Vilprafen Solyutab / hormonal contraceptives
In rare instances the contraceptive effect of hormonal contraceptives can be insufficient during treatment macroleads. In this case it is recommended to use non-hormonal contraceptives in addition.

Contraindications:

- hypersensitivity to antibiotics to macroleads
- heavy abnormal liver functions

Pregnancy and lactation. Use at pregnancy and during breastfeeding according to indications is authorized. The European department of WHO recommends джозамицин as choice drug at treatment of a chlamydial infection at pregnant women.

Overdose:

There are no data on specific symptoms of poisoning so far. In case of overdose it is necessary to assume emergence of the symptoms described in the section "Side effects", especially from digestive tract.
If one reception is missed, it is necessary to accept a drug dose immediately. However, if time of reception of the following dose came, it is not necessary to accept the "forgotten" dose, and it is necessary to return to the usual mode of treatment. It is not necessary to accept the doubled dose. Having rummaged in treatment or the premature termination of administration of drug reduce probability of success of treatment.

Storage conditions:

Period of validity 2 years. Vilprafen Solyutab it is not necessary to apply after the expiry date specified on packaging. Storage conditions. List B. To store in the dry place protected from light at a temperature not above 25 °C. To store medicine in the places unavailable to children!

Issue conditions:

According to the recipe

Packaging:

Tablets the dispersed 1000 mg.
Standard packaging:
On 5 or 6 tablets dispersed in the blister manufactured of a polyvinyl chloride film and aluminum foil. On 2 blisters together with the application instruction in a cardboard pack.